Rivaroxaban for heart clots in children
Treatments studied
Part of Blood & lymphatic, Heart & circulation clinical trials.
This study tests a blood thinner called rivaroxaban in children who have a blood clot inside the heart. The goal is to see if it safely and effectively dissolves the clot, potentially avoiding the need for stronger treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must have a blood clot inside the heart, confirmed by an echocardiogram and another imaging test (like an MRI or CT scan).
- You or your child's legal guardian must sign a consent form agreeing to participate.
- Your child must have been born at full term (38 weeks or more of pregnancy).
- Your child must have been taking milk or food by mouth for at least 10 days and weigh at least 2.6 kilograms (about 5.7 pounds).
- In the past 10 days, your child must not have had any major bleeding problems or abnormal blood clotting test results.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how well blood thinners (anticoagulants) work to dissolve clots in the heart of people with atrial fibrillation (an irregular heartbeat). It aims to find the best treatment for these clots before more serious complications occur.
This study looks at how rivaroxaban (and sometimes other blood thinners) are used in babies under 2 who have venous thromboembolism (VTE), a blood clot in a vein. It gathers real-world safety information to help doctors understand how well this treatment works and what side effects may happen.
This trial is testing the drug rivaroxaban in children aged 2 to 17 who have large bulges (aneurysms) in their heart arteries after Kawasaki disease. It aims to see how the drug works in the body to prevent blood clots.
This trial studies whether rivaroxaban (a blood thinner) can help prevent dangerous clots in children age 2 and older who have “giant” coronary artery aneurysms after Kawasaki disease. Doctors will see if it’s safe and tolerable for children who are also on standard anti-clot/anti-platelet medications for the next 3 months.
This trial studies whether a specific blood thinner can better treat a left-side heart clot found soon after a heart attack. It may help prevent the clot from getting worse or causing complications.
This trial tests a blood thinner called rivaroxaban (Xarelto) given right after heart valve surgery with a tissue valve. It aims to see if it can prevent blood clots or strokes safely in the early recovery period.
Hear when a new Intracardiac Thrombus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.